17 results about "Clotting time" patented technology

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The present invention relates to a method and apparatus for determining the activity of clotting factors in diluted capillary whole blood, citrated whole blood and citrated plasma. The invention also includes the detection of hemoglobin content in the whole blood sample to correct for clotting time so that the clotting time values are not affected by hemoglobin and hematocrit.

The invention belongs to the technical field of blood coagulation accelerators, and particularly relates to an efficient dispersion coagulation accelerator as well as a preparation method and application thereof. The method comprises the following steps: at 65-80 DEG C, dissolving an inorganic salt procoagulant substance in an aqueous solution system containing a film-forming agent and a dispersing agent to react for 1-2 hours, then mixing with an ethanol solution in which polydimethylsiloxane is dissolved, adding a compound emulsifier, and then homogenizing and uniformly stirring at a high speed to obtain the efficient dispersion coagulant. The preparation method is simple in process and easy to operate, and raw materials are rich in source and easy to obtain. The high-efficiency dispersion coagulant is a suspension homogeneous liquid, has no obvious layering, has the pH value of 6-7 and the solid content of 7-8%, has the blood coagulation time as low as 8 minutes or less, is subjected to centrifugal treatment after blood coagulation, is complete in serum separation, and has no fibrin filament wall hanging and hemolysis phenomena. The blood collection container containing the efficient dispersion coagulant is used for 30 clinical biochemical tests, and the repeatability of the test result of the same clinical patient is good.

A polypeptide comprising: a) milk-clotting enzyme activity, wherein the C / P ratio of clotting activity (C) to proteolytic activity (P) is equal to or greater than the C / P ratio of a polypeptide having the amino acid sequence of SEQ ID NO: 2; and b) alpha-S1-I casein fragment generating activity that is equal to or greater than the alpha-S1-I casein fragment generating activity of a polypeptide having the amino acid sequence of SEQ ID NO: 2; and / or c) a clotting time at pH 6.1 that is equal to or less than the clotting time of a polypeptide having the amino acid sequence of SEQ ID NO: 2.

Various embodiments of the invention utilize chalcones to treat blood, bleeding, and / or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, chalcones reduce blood clotting time and increase blood clotting efficiency without any apparent risk of immunogenicity or unwanted blood clots. As also described herein, chalcones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

The present invention relates to antibodies and antigen-binding fragments thereof that specifically bind to TFPI and inhibit its activity. These antibodies and fragments can be used to treat hemorrhagic disorders and shorten the clotting time.

The invention discloses a traditional Chinese medicine composition for relieving itching. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-50g of radix scutellariae, 6-50g of fructus gardeniae, 6-50g of fructus forsythiae, 6-50g of flos lonicerae and 6-50g of radix geutianae. According to the invention, the radix scutellariae for inhibiting histamine release, the fructus forsythiae for antagonizing histamine receptors and the felwort for blocking itching signal transduction are subjected to multi-way action to cover the whole link of itching-inducing medium generation-receptor combination-signal transmission, so that rapid itching relieving is realized; the cape jasmine for promoting prothrombin activation, the baical skullcap root for enhancing platelet aggregation and the honeysuckle flower for contracting blood vessels act together, so that the blood coagulation time is shortened, and the effect fluctuation of a single hemostasis mechanism is avoided; the five medicines jointly inhibit the release of inflammatory factors, enhance the local antibacterial ability, relieve inflammatory pruritus, prevent wound infection, avoid vicious circle of itching-grasping-infection-aggravated itching, and reduce the infection risk after bleeding.

The application belongs to the technical field of biomedical materials, and provides an anti-inflammatory hemostatic composite gel microsphere and a preparation method and application thereof, and comprises the following steps: mixing sodium alginate and baicalin to be dissolved in deionized water to obtain a mixed solution, spraying the mixed solution into a calcium chloride solution by using electrostatic spraying, and forming gel microspheres through ion cross-linking; rinsing the gel microspheres with a calcium chloride solution, and then immersing the gel microspheres in a chitosan acetic acid solution to obtain chitosan-coated gel microspheres; placing the gel microspheres in a copper sulfate solution, and performing low-temperature calcium-copper ion exchange to obtain baicalin / copper alginate composite gel microspheres; and filtering, washing and freeze-drying the composite gel microspheres. Through the electrostatic spraying technology combined with ion cross-linking, the application realizes accurate control of the size and morphology of the microspheres, has a significant bacteriostatic effect on escherichia coli and staphylococcus aureus, shortens the in-vitro blood clotting time by 30%, has low cytotoxicity, and has good biocompatibility.

The application discloses a multi-association coagulation time detection instrument and reagent card, and relates to the field of medical devices.The instrument comprises an instrument body, a reagent card channel for reagent card insertion, a first sensor and a second sensor arranged on the instrument body, the first sensor being used for detecting one end of a test channel on the reagent card, and the second sensor being used for detecting a waste liquid channel of the reagent card; a driving module, which is in communication with the waste liquid channel and the test channel respectively; and a control processing unit, which is in signal connection with the driving module, the first sensor and the second sensor respectively.After the above-mentioned instrument is used, a plurality of coagulation items can be tested at a time, each test channel can individually and accurately quantify a sample, and the blood sample and the reagent can be effectively mixed, so that the sample in the test channel can be prevented from being sucked into an air path, the waste liquid sample in the waste liquid channel can be prevented from flowing back, whether the added sample is excessive or insufficient can be detected, and the hematocrit of blood can be accurately detected.

A device for performing coagulation tests that measure clotting time and clot characteristics in a whole blood sample under different hemostatic conditions. The test results are used to aid in the management of patients with coagulopathy of unknown etiology, helping the physician determine the appropriate clinical action to stop bleeding.

Various embodiments of the invention utilize flavanones, including, but not limited to, 3-hydroxyflavone compounds and 3-hydroxyflavone sugar compounds, to treat blood, bleeding, and / or bleeding disorders. As described herein, flavanones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, flavanones reduced blood clotting time and increased clotting efficiency in blood without any apparent risk of immunogenicity or risk of unwanted blood clots. As also described herein, flavanones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

The invention discloses a double logarithmic calibration method based on a reagent for a blood coagulation analyzer, and relates to the technical field of in vitro diagnosis, and the method comprises the following steps: based on the deviation of temperature and turbidity, performing fractional normalization anti-interference correction on a detection signal through a detection signal correction function, obtaining a corrected detection signal, and generating a corrected detection signal curve; combining the corrected detection signal with an initial double logarithm calibration equation to generate a predicted concentration, comparing the predicted concentration with a reference concentration to obtain a concentration deviation, and generating an anti-interference correction response amount according to the solidification time in the corrected detection signal curve; on the basis of the anti-interference correction response quantity, calculating a double logarithmic residual error of the test sample, associating the double logarithmic residual error with the concentration deviation, and performing real-time step length adjustment on a coefficient in a detection signal correction function according to a residual error direction to generate an updated double logarithmic calibration equation. According to the invention, the accuracy and robustness of the double logarithmic calibration equation are improved.

This invention relates to a gene encoding coagulation factor IX. F9 This study investigates animal models of nonsense mutations, methods for screening hemophilia drugs using these models, and the application of the screened stRNAs in the preparation of hemophilia drugs. Based on an analysis of the probability of nonsense mutations in coagulation factor IX in hemophilia patients, the study verifies that stRNAs can read the coagulation factor IX encoding gene. F9 The function and efficiency of the premature termination codon (PTC) were investigated. Seven Arg-stRNAs were designed to target the coagulation factor IX R75* mutation, and readthrough efficiency was tested at the cellular level. A mouse model of the coagulation factor IX R75* mutation was constructed, and Arg-stRNA was delivered via AAV, restoring the expression of endogenous coagulation factor IX and reducing clotting time, demonstrating the effectiveness of stRNA in treating hemophilia B.

A cause of prolongation of a blood clotting time for a test sample is estimated by acquiring a clot waveform showing a change in light amount over time according to a coagulation reaction of a reaction liquid. A first waveform is acquired by performing before-after differentiation processing on the clot waveform. First and second fitted waveforms are acquired by performing fitting processing on the clot waveform and the first waveform. A third waveform is acquired by performing before-after differentiation processing on the second fitted waveform. First to third normalized waveforms are acquired by normalizing the first and second fitted waveforms and the third waveform, respectively, on a light amount axis and a time axis. A feature from each of the first to third normalized waveforms is extracted; and the cause of prolongation of a blood clotting time is estimated based on a known feature and the extracted feature.

The embodiment of the invention relates to a blood coagulation analyzer, a fibrinogen analysis method and a clinical decision support system. The blood coagulation analyzer comprises a sample preparation part which is used for preparing a determination sample by using to-be-detected plasma from a to-be-detected blood sample and a detection reagent; the detection part is used for detecting the test sample; the controller is used for acquiring detection information representing reduction of fibrinogen in the to-be-detected plasma, and responding to the detection information: controlling the sample preparation part to prepare a first determination sample at a first dilution ratio and a second determination sample at a second dilution ratio, and controlling the detection part to respectively detect the first determination sample and the second determination sample, and determining the cause of fibrinogen reduction in the to-be-detected plasma at least according to the first coagulation time and the first dilution ratio, the second coagulation time and the second dilution ratio and a reference curve, and the reference curve represents the relationship between the coagulation time and the dilution ratio of the reference plasma.

A microfluidic, chip-based assay device has been developed for measuring the physical properties of an analyte (specifically, whole blood or whole blood derivatives). The technologies can be applied to measure the clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, and evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulant drugs and / or their reversal agents.The assay is anticoagulant-independent - clotting is initiated by exposing the blood sample within the device to a glass surface (or other negatively charged material such as oxidized silica), which activates the intrinsic pathway and can be further accelerated by applying shear flow across the surface of the activating materials. The absence of chemical activating agents and a highly controlled and reproducible microenvironment yield a universal point-of-care clotting assay.

Various embodiments of the invention utilize flavanones, including, but not limited to, 3-hydroxyflavone compounds and 3-hydroxyflavone sugar compounds, to treat blood, bleeding, and / or bleeding disorders. As described herein, flavanones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, flavanones reduced blood clotting time and increased clotting efficiency in blood without any apparent risk of immunogenicity or risk of unwanted blood clots. As also described herein, flavanones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.